NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...
Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...
Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE: NVO) is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...